Skip to content

OPIANT PHARMACEUTICALS, INC.: 10-K/A filed 2012-11-01

What OPIANT PHARMACEUTICALS, INC. reported in its annual report amendment filed 2012-11-01 (fiscal FY 2012): 27 published measures, 79 facts as tagged in accession 0001185185-12-002354.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2012-11-01
Fiscal period
fiscal FY 2012
Accession
0001185185-12-002354 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-07-3144,976USD
At 2011-07-3177,715USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-07-31663,694USD
At 2011-07-31416,232USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-07-31-618,718USD
At 2011-07-31-338,517USD
At 2010-07-31-637,287USD
At 2009-07-31290USD
At 2008-07-31-28,154USD
At 2007-07-31-10,230USD
At 2006-07-3123,375USD
At 2005-07-310USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-07-3120,423USD
At 2011-07-3151,789USD
At 2010-07-312,300USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-08-01 to 2012-07-31-12,421,188USD366
2005-06-21 to 2012-07-31-23,928,895USD2598
2010-08-01 to 2011-07-31-9,435,787USD365
2009-08-01 to 2010-07-31-2,016,710USD365
2008-08-01 to 2009-07-3128,444USD365
2007-08-01 to 2008-07-31-17,924USD366
2006-08-01 to 2007-07-31-33,605USD365
2005-08-01 to 2006-07-31-32,125USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-08-01 to 2012-07-31-1,096,738USD366
2005-06-21 to 2012-07-31-4,486,438USD2598
2010-08-01 to 2011-07-31-2,955,913USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-08-01 to 2012-07-310USD366
2005-06-21 to 2012-07-310USD2598
2010-08-01 to 2011-07-310USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-08-01 to 2012-07-311,065,372USD366
2005-06-21 to 2012-07-314,506,861USD2598
2010-08-01 to 2011-07-313,005,402USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-08-01 to 2012-07-310USD366
2005-06-21 to 2012-07-310USD2598
2010-08-01 to 2011-07-310USD365

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-08-01 to 2012-07-31103,881,283shares366
2010-08-01 to 2011-07-3167,163,719shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-08-01 to 2012-07-31-0.12USD/shares366
2010-08-01 to 2011-07-31-0.14USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-08-01 to 2012-07-310USD366
2005-06-21 to 2012-07-310USD2598
2010-08-01 to 2011-07-310USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-08-01 to 2012-07-311,027,501USD366
2005-06-21 to 2012-07-311,558,751USD2598
2010-08-01 to 2011-07-31531,250USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-08-01 to 2012-07-31-12,335,706USD366
2005-06-21 to 2012-07-31-23,886,576USD2598
2010-08-01 to 2011-07-31-9,435,787USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-07-3120,423USD
At 2011-07-3151,789USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-08-01 to 2012-07-313,997USD366
2005-06-21 to 2012-07-313,997USD2598

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-08-01 to 2012-07-3112,335,706USD366
2005-06-21 to 2012-07-3123,886,576USD2598
2010-08-01 to 2011-07-319,435,787USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-08-01 to 2012-07-31506,169USD366
2005-06-21 to 2012-07-31506,169USD2598

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-07-31126,083,416shares
At 2011-07-3176,976,333shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-07-3123,184,094USD
At 2011-07-3111,092,214USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2012-07-3124,553USD
At 2011-07-3125,926USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2012-07-310USD
At 2011-07-310USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-08-01 to 2012-07-3111,829,537USD366
2005-06-21 to 2012-07-3123,341,392USD2598
2010-08-01 to 2011-07-319,435,787USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-08-01 to 2012-07-311,373USD366
2005-06-21 to 2012-07-312,897USD2598
2010-08-01 to 2011-07-311,016USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-08-01 to 2012-07-31-85,482USD366
2005-06-21 to 2012-07-31-42,319USD2598

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-08-01 to 2012-07-31802,929USD366
2005-06-21 to 2012-07-313,936,449USD2598
2010-08-01 to 2011-07-313,078,020USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-08-01 to 2012-07-31-48,639USD366
2005-06-21 to 2012-07-3155,497USD2598
2010-08-01 to 2011-07-31-99,772USD365

Inspect the source

Entity
OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
Captured
SEC response SHA-256
2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))